Trajenta Duo 2.5/500mg Tablet belongs to the therapeutic classification of Antidiabetic Agents. The primary composition for this medicine is Linagliptin 2.5 MG, Metformin 500 MG.

Trajenta Duo 2.5 mg /500 mg Tablet 10's should not be used in patients with type 1 diabetes or with diabetic ketoacidosis. Some diabetic patients, while taking Trajenta Duo 2.5 mg /500 mg Tablet 10's, might develop a rare but serious condition called lactic acidosis. In this condition, there is too much lactic acid accumulated in the blood that can damage the working of your liver and kidney required for the elimination of excess lactic acid from the blood. Before you start taking Trajenta Duo 2.5 mg /500 mg Tablet 10's, tell your doctor if you’ve ever had pancreatitis (inflammation of the pancreas), kidney disease, and low vitamin B12 level. Trajenta Duo 2.5 mg /500 mg Tablet 10's, when used with insulin, may extremely lower the blood sugar level leading to hypoglycemia condition, which can be fatal. Your doctor may adjust the dose by lowering the dose of insulin or Trajenta Duo 2.5 mg /500 mg Tablet 10's in this case. A prolonged intake of Trajenta Duo 2.5 mg /500 mg Tablet 10's may lower your thyroid-stimulating hormone (TSH); hence, TSH's annual check-up is recommended. You may also develop a serious skin reaction known as bullous pemphigoid that requires immediate medical attention in rare cases. Tell your doctor if you will have a diagnostic test with an injection of dye or X-ray contrast agent. The use of Trajenta Duo 2.5 mg /500 mg Tablet 10's should be stopped for a short time before having an X-ray procedure.